Strategic Partnerships Certis Oncology has recently announced multiple strategic collaborations in 2026 with Perceptive Group, Perceptive Discovery, and Bioemtech to advance radiopharmaceutical development and provide PDX models. These partnerships indicate a growing openness to co-development and external validation, presenting opportunities to position complementary predictive analytics, expanded model libraries, or joint go-to-market offerings.

AI Platform Launch The launch of the Oncology Intelligence platform in March 2026 signals a mature, customer-facing AI/ML solution that integrates predictive analytics with biological validation. This creates a pathway to upsell enhanced data services, licensing of predictive insights, and advisory engagements around clinical development strategy for pharma companies seeking higher success probabilities.

Clinical Model Capabilities Certis operates a CLIA-certified, AAALAC- and OLAW-accredited lab with patient-derived tumor models, enabling translational testing and real-world relevance. This positioning can be leveraged to offer end-to-end translational services, from predictive modeling to functional validation, appealing to pharmaceutical sponsors aiming to de-risk candidate selection.

Financial Footing With a revenue range of tens of millions and a funding level around ten million, Certis appears to be in a growth phase with active investment in AI platforms and partnerships. This suggests selling opportunities around scalable pilot programs, phased engagements, and value-based pricing aligned with accelerating development timelines.

Leadership and Visibility Recent leadership changes and high-profile board activity, including a new chairman appointment after a funding round, indicate ongoing corporate evolution and signaling to investors and partners. This environment presents opportunities to engage at the executive level with strategic roadmaps, channel partnerships, and collaboration proposals aligned to their expansion ambitions.